



JOURNAL EDITOR-IN-CHIEF'S REVIEW REPORT

Name of journal: World Journal of Virology

Manuscript NO: 59283

Title: Reinfection risk of novel coronavirus (COVID-19): A systematic review of current evidence

Journal Editor-in-Chief (Associate Editor): Mahmoud El-Bendary

Country/Territory: Egypt

Editorial Director: Ze-Mao Gong

Date accepted review: 2020-11-13 00:22

Date reviewed: 2020-11-13 01:34

Review time: 1 Hour

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> Major revision

JOURNAL EDITOR-IN-CHIEF (ASSOCIATE EDITOR) COMMENTS TO AUTHORS

The review is very interesting as it raise an important question: Is there reinfection or reactivation of the COVID-19 after cure from the infection. But some comments to be considered. - Where the inclusion criteria of the included papers in this meta-analysis, only exclusion criteria were included. - The 1st case report by Aldhaleei et al [10] describe HBV reactivation induced by COVID-19 and so has no relation to our title here so must be deleted from the metaanalysis. - What the definition of reinfection or reactivation of COVID-19? what is the duration must be calculated to differentiate between reinfection or reactivation? Actually up till now there is no definite definition. for example some studies claim that neutralizing immunoglobulins against SARS-CoV-2 persist for about 40 days. so in your analysis you must not just mention the abstract of every study but you must tabulate the data of all studies as follow - 1st classify the all patients recruited in these studies into 2 groups immunocompromised and non immunocompromised - what is the duration between the 1st and



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

2nd episodes. because in some studies it was about few days which may mean persistence of infection rather than reinfection. What was the discharge criteria: it was only clinical without PCR as this is the policy of most hospitals nowadays. What are the criteria of reactivation or reinfection, clinical, radiological or definite PCR without clinical or laboratory diagnosis. - Are there any comorbid conditions - is there a risk of exposure after discharge? - is there sequencing or genotyping of the strain to differentiate between reinfection and reactivation? - The reference No. (25) 1st author is Gousseff. M, not Batisse. D Clinical recurrences of COVID-19 symptoms after recovery: Viral relapse, reinfection or inflammatory rebound? Marie Gousseff,k,1,* Pauline Penot,r,1 Laure Gallay,i,1 Dominique Batisse,a,1 Nicolas Benech,b,1 Kevin Bouiller,e,f,1 Rocco Collarino,g,1 Anne Conrad,h,1 Dorsaf Slama,t,1 Cédric Joseph,l,1 Adrien Lemaignan,m,1 François-Xavier Lescure,n,o,1 Bruno Levy,p,1 Matthieu Mahevas,q,1 Bruno Pozzetto,s,1 Nicolas Vignier,u,1 Benjamin Wyplosz,v,1 Dominique Salmon,t,1 François Goehring,j,1,* Elisabeth Botelho-Nevers,c,d,1 and in behalf of the COCOREC study group - The discussion is very deficient you must answer the following questions Can SARS - CoV - 2 re - infect the individuals who recovered from COVID - 19? This question is also associated with other questions: whether or not SARS - CoV - 2 infection induces protective reaction or neutralized antibody? Will SARS - CoV - 2 vaccines work? (b) Why could some recovered patients with COVID - 19 be re - tested positive for SARS - CoV - 2 RNA? (c) Are some recovered COVID - 19 patients with re - testing positive for SARS - CoV - 2 RNA infectious? (d) How should the COVID - 19 patients with retest positive for SARS - CoV - 2 be managed? - There are some words stuck together with spaces eliminated. Reread the manuscript and correct these errors. varicella-zoster can remain ---> varicella-zoster can remain , 2 reactivation in --- reactivation in. aforementioned --- fore mentioned. -